1. Metastatik Kolorektal Kanserli Hastaların RAS Mutasyon Durumuna Göre Klinik ve Patolojik Özellikleri
   Mehmet SEZEN et al, 2019, Uludağ Üniversitesi Tıp Fakültesi Dergisi CrossRef
2. Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka
   Sharmin Chowdhury et al, 2022, Advances in Cancer Biology - Metastasis CrossRef
3. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing–based cohort study
   Mayank Jauhri et al, 2017, Tumor Biology CrossRef
4. Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis
   Xin-Ya Du et al, 2017, Oncotarget CrossRef
5. Phytochemicals from Allium tuberosum Rottler ex Spreng Show Potent Inhibitory Activity against B-Raf, EGFR, K-Ras, and PI3K of Non-Small Cell Lung Cancer Targets
   Rajat Nath et al, 2022, Applied Sciences CrossRef
6. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
   Jiao Yang et al, 2016, Tumor Biology CrossRef
7. Prevalence of BRAF gene mutation in samples of primary and metastatic colorectal cancer: A meta‐analysis
   Mahmood Moosazadeh et al, 2019, European Journal of Cancer Care CrossRef
8. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
   T. Yoshino et al, 2018, Annals of Oncology CrossRef
9. Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort
   Michael Levi et al, 2018, Journal of Gastrointestinal Cancer CrossRef
10. METASTATİK KOLOREKTAL KANSERLİ HASTALARIN EGFR YA DA VEGF İNHİBİTÖRÜ KULLANIM DURUMLARINA GÖRE KLİNİK ÖZELLİKLERİNİN İNCELENMESİ
    Metin Deniz KARAKOÇ et al, 2023, Kocatepe Tıp Dergisi CrossRef